← Back
Nuvation Bio
NUVB · listed on the New York Stock Exchange · worth $2.05 billion
$4.76
+0.85% on Nov 4
One insider buy in the last year, $118.3K in all. None in the last two weeks.
Green dot = an insider bought red = sold◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
263.6M shares
75% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, one insider bought Nuvation Bio stock and six insiders sold. One of the 13 sales is marked on the filing as planned in advance; all by company executives. The biggest seller was Gary Hattersley, CHIEF SCIENTIFIC OFFICER.
How each buyer's earlier purchases went: the stock about six months later, beside the S&P 500 over the same days. Purchases planned in advance are left out. Past results, not a forecast.
Director
Robert Mashal
Bought $118.3K on Jun 9 — 25,000 shares at $4.73, held through a trust or family, 11% of what they now own.
First purchase we have on file
Planned sales
Form 144 notices filed for Nuvation Bio in recent months, beside the Form 4 sales reported after each. A notice says a person intends to sell; it is not a sale.
Executive Gary Hattersley filed to sell 100,000 shares on 19 Aug; sold 100,000 by 19 Aug10b5-1 plan adopted 4 Dec 2025 · Notice on SEC.gov
Big investors
People and funds that reported owning 5% or more of Nuvation Bio, newest first.
Filed by someone who owns 5% or more and does not plan to influence the company.BlackRock6.4%Jul 17, 2025Reported stake, oldest first: 4.9% (Apr 28, 2025) → 6.4% (Jul 17, 2025)
Filed by someone who owns 5% or more and does not plan to influence the company. · updateFMR LLC15.0%May 12, 2025Reported stake, oldest first: 11.9% (Dec 6, 2024) → 13.5% (Feb 12, 2025) → 15.0% (May 12, 2025)
Filed by someone who owns 5% or more and does not plan to influence the company. · updateBlackRock4.9%Apr 28, 2025
Filed by someone who owns 5% or more and does not plan to influence the company. · updateFMR LLC13.5%Feb 12, 2025
Filed by someone who owns 5% or more and does not plan to influence the company. · updateFMR LLC11.9%Dec 6, 2024
Each history starts at the oldest report we hold.
All reports
Every insider trade and SEC report we hold for Nuvation Bio.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Aug 21SoldGary HattersleyAug 21 · Traded Aug 19 · CHIEF SCIENTIFIC OFFICER · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.100,000 @ $7.09$709.2K
Jun 11BoughtRobert MashalJun 11 · Traded Jun 9 · Director+11%via a trust or family25,000 @ $4.73$118.3K
17 more with Pro →Analysts, earnings and news
Analysts' price target
$12.33 average
9 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
2 of 4 quarters above
Q1 '26$0.04 a share−$0.01
Q4 '25−$0.09 a share−$0.04
Q3 '25−$0.14 a share+$0.01
Q2 '25−$0.14 a share+$0.00